• Mineralys Therapeutics reported that long term efficacy and safety data from its Transform-HTN open label lorundrostat trial will be presented as late breaking science at the American Heart Association Scientific Sessions 2026 in Chicago.
• The focus on uncontrolled and resistant hypertension, chronic kidney disease and obstructive sleep apnea highlights how lorundrostat could support a multi indication cardiorenal portfolio if future approvals are achieved.
• We assess how Mineralys Therapeutics' investment narrative could be influenced by the late breaking Transform HTN data disclosure.

Compare Mineralys Therapeutics' cardiorenal focus with other potential beneficiaries of the same trend by scanning our curated 35 healthcare AI stocks, which could also be shaping future treatment pathways.

Mineralys Therapeutics Investment Narrative Recap

To own Mineralys Therapeutics, you need to believe lorundrostat can move from a single asset in trials to a commercial hypertension and broader cardiorenal franchise. The biggest near term swing factor is progress toward an NDA filing in uncontrolled and resistant hypertension. The newly flagged long term Transform HTN data looks directionally helpful for that story but does not change the core bet.

The main risk remains binary. Lorundrostat is still unapproved, Mineralys has no product revenue and it is spending to build out trials and commercial readiness while reporting losses, including a US$349.6 million loss. If regulators request more data or timelines slip, funding needs and dilution risk rise.

The late breaking Transform HTN presentation is the most relevant update for investors tracking Mineralys Therapeutics. Management is putting long term efficacy and safety into the spotlight at a major cardiology meeting, after already running six late stage studies that support aldosterone as a target in hard to treat hypertension.

The real value from this disclosure will depend on how the data align with prior Launch HTN and Advance HTN results and how clinicians respond to durability and tolerability signals. That feeds directly into the NDA package and potential positioning against other aldosterone synthase inhibitors. It will also influence how far existing cash that is guided to last into 2028 can carry the company toward a possible commercial stage.

Mineralys Therapeutics' narrative projects US$467.2 million revenue and US$16.6 million earnings by 2029. This implies earnings would move by about US$366.2 million from a loss of US$349.6 million today to the forecast profit level in 2029.

Uncover why Mineralys Therapeutics' fair value indicates a 105% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

The most optimistic analysts on Mineralys Therapeutics lean hard into the commercialization catalyst. Before this AHA late breaking Transform HTN spotlight was even on the calendar, they were already modeling US$387.9 million of revenue and US$48.5 million of earnings potential by 2029 along with a rich 143x P/E. You might read the new long term data and Stifel forum commentary very differently, so treat these pre news forecasts as just one side of the debate and explore how your own expectations compare.

Explore 3 other Mineralys Therapeutics fair value estimates, including one that suggests potential upside of up to 907% from the current price.

Decide For Yourself

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

• A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Mineralys Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.

Looking For More Investment Ideas Beyond Mineralys Therapeutics?

Once you have a view on Mineralys Therapeutics, it can help to cross check that thinking against other opportunities using the Simply Wall St Screener, so you see where risk, quality and valuation line up best for you.

• If you want potential upside without stretching your budget, scan a focused group of smaller, higher risk opportunities through the 8 elite penny stocks with strong financials.
• For investors who care most about paying a reasonable price for quality, compare Mineralys Therapeutics with a curated 31 high quality undervalued stocks that already clear basic balance sheet and earnings tests.
• If capital preservation sits near the top of your checklist, start with a 31 resilient stocks with low risk scores that our models flag with relatively resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.